“In pharma, the focus is now shifting to the CDMO space, which has been an underperformer. We have seen some uptick in Divis, Laurus. Newland has done very well. This space looks the most attractive from a long-term perspective. One can also look selectively at hospitals, ” says Gurmeet Chadha.